Last reviewed · How we verify
ALKS 33
At a glance
| Generic name | ALKS 33 |
|---|---|
| Also known as | ALKS 33: RDC-0313. |
| Sponsor | Alkermes, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ALKS 3831 in Adults With Schizophrenia (PHASE2)
- A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers (PHASE1)
- A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users (PHASE1)
- ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine (PHASE1)
- ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD (PHASE1, PHASE2)
- ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |